



Published on NAVADHI Market Research (<https://www.navadhi.com>)

[Home](#) > Global Antirheumatics Pharmaceutical Market Forecast 2023

## Global Antirheumatics Pharmaceutical Market Forecast 2023



**Publication ID:**

NAV0619017

**Publication Date:**

June 12, 2019

**Pages:**

267

**Countries:**

[Global](#) [1]

**Publication License Type \***

Single User License (PDF), \$2,000.00

Enterprise License (PDF), \$3,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart

Add to wish list



Global antirheumatics market is expected to grow in near future as aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases help increase the demand for various arthritis treatments.

Global antirheumatics market is expected to be worth USD 56.88 billion by 2023.

As per NAVADHI Market Research, global antirheumatics pharmaceutical market will be worth USD 56.88 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

Antirheumatics had the second largest revenue share in Global pharmaceuticals market in FY 2018, and it is expected to retain its position even in 2023.

As per industry sources, about 1.3 million people suffer from rheumatoid arthritis (RA) in United States, 2.9 million in European Union and 1.4 million in Japan and most of the patients are women. With the increasing lifespans due to improved healthcare facilities more and more people are prone to rheumatoid arthritis.

This growth in antirheumatics market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global antirheumatics industry. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and specialty diseases market. Innovations in advanced biologics, nucleic acid therapeutics and cell therapies has attracted investments in the industry which is fueling this growth.

On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global antirheumatics industry. Antirheumatics companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the global antirheumatics market as new drugs revenue form large part of pharma firm's revenue due to exclusivity of the drug. Competition from generic manufacturers is also a concern for major brands. For example - Cipla in 2013 launched the biosimilar of etanercept under brand name Etacept for the treatment of rheumatic disorders which was cheaper alternative of Amgen and Pfizer's hugely successful Enbrel brand.

On 3rd January 2019, Bristol-Myers Squibb Company which was ranked 7th based on their FY 2018 antirheumatics revenue announced their plan to acquire Celgene Corporation which was ranked 10th in the world for antirheumatics revenue. The acquisition is expected to cost around USD 90 billion to Bristol-Myers Squibb Company. Post-acquisition Bristol-Myers Squibb Company is expected to give tough competition to Pfizer for 3rd spot in global antirheumatics revenue.

Spanning over 267 pages and 180 exhibits, "Global Antirheumatics Pharmaceutical Market Forecast

2023” report provides in-depth analysis for the global antirheumatics pharmaceuticals market for the year FY2018 to FY2023, including market structure, market trends, market constraints and industry drivers.

This report includes detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global antirheumatics market namely: AbbVie Inc., Amgen Inc., Pfizer Inc., Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb, Merck & Co., Inc., UCB S.A. and Eli Lilly and Company

## **Scope of the Global Antirheumatics Pharmaceutical Market Forecast 2023 Report**

- This report provides detailed information about Global antirheumatics market including future market forecasts till 2023.
- This report identifies the need for focusing on global antirheumatics market.
- The report identifies the growth drivers and inhibitors for global antirheumatics market.
- The report identifies various risks associated with global antirheumatics market.
- This report has detailed profiles of 10 key players in Global antirheumatics market covering their business strategy, financial performance, future forecasts and SWOT analysis.
- This report provides competitive landscape among top 10 key companies in Global antirheumatics market.
- This report provides Porter’s Five Forces analysis for Global antirheumatics market.
- This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Global antirheumatics market.
- This report provides information about current and future trends for Global antirheumatics market.

## **1. Executive Summary**

Scope of the Global Antirheumatics Pharmaceutical Market Forecast 2023 Report  
Research Methodology

## **2. Introduction of Pharmaceuticals Industry**

Key Product Terms Used in Pharmaceuticals Industry

Pharmaceuticals

Innovative Drugs

Orphan Drugs

Generic Drugs

Commodity Generic Drugs

Branded Generic Drugs

Biologics

Biosimilars

Over-the-counter (OTC) Drugs

Active Pharmaceutical Ingredients (APIs)

Excipients

Research and Development (R&D) Phases of Pharmaceuticals Industry

Industry-Wise Research and Development (R&D) Investment

Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry

Global Pharmaceuticals Industry Value Chain Analysis

### **3. Need for Global Antirheumatics Market**

Rising & Ageing Global Population  
Increasing Income Levels of Poor & Middle-Class Families

### **4. Forecast for Global Antirheumatics Market 2023**

4.1 Therapy Area-Wise Forecast for Global Pharmaceuticals Market 2018-2023

4.1.1 Forecast for Global Antirheumatics Pharmaceuticals Market 2018-2023

### **5. Growth Drivers and Inhibitors for Global Antirheumatics Market**

### **6. Risks Associated with Global Antirheumatics Market**

### **7. Industry Associations Related to Global Pharmaceuticals Market**

7.1 European Federation of Pharmaceutical Industries and Associations (EFPIA)

7.2 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)

7.4 Association of the British Pharmaceutical Industry (ABPI)

7.5 Japan Pharmaceutical Manufacturers Association (JPMA)

7.6 Indian Drug Manufacturers' Association (IDMA)

### **8. Profile of Key Players in Global Antirheumatics Market**

#### **8.1 Pfizer Inc.**

8.1.1 Company Profile

8.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain

8.1.3 Pfizer Inc.: Financial Performance

8.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)

8.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)

8.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)

8.1.4 Pfizer Inc.: Business Strategy

8.1.4.1 Product Level Strategy

8.1.5 SWOT Analysis of Pfizer Inc.

Strengths

Weaknesses

Opportunities

Threats

#### **8.2 Novartis AG**

8.2.1 Company Profile

8.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain

8.2.3 Novartis AG: Financial Performance

8.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)

8.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)

8.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)

8.2.4 Novartis AG: Business Strategy

8.2.5 SWOT Analysis of Novartis AG

Strengths

Weaknesses

Opportunities

Threats

### **8.3 Johnson & Johnson**

8.3.1 Company Profile

8.3.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain

8.3.3 Johnson & Johnson Financial Performance

8.3.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)

8.3.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)

8.3.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)

8.3.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)

8.3.4 Johnson & Johnson: Business Strategy

8.3.4.1 Product Level Business Strategy

8.3.5 Johnson & Johnson's Pharmaceutical Division Growth Drivers

8.3.6 SWOT Analysis of Johnson & Johnson

Strengths

Weaknesses

Opportunities

Threats

### **8.4 Amgen Inc.**

8.4.1 Company Profile

8.4.2 Amgen Inc. in Global Pharmaceuticals Manufacturing Value Chain

8.4.3 Amgen Inc: Financial Performance

8.4.3.1 Amgen Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)

8.4.3.2 Amgen Inc.: Geography-Wise Revenue FY 2018 (in USD billion)

8.4.3.3 Amgen Inc.: Division-Wise Revenue FY 2018 (in USD billion)

8.4.3.4 Amgen Inc.: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)

8.4.3.5 Amgen Inc.: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)

8.4.4 Amgen Inc.: Business Strategy

8.4.4.1 Product Level Strategy

8.4.5 SWOT Analysis of Amgen Inc.

Strengths

Weaknesses

Opportunities

Threats

### **8.5 Roche Holding AG**

8.5.1 Company Profile

8.5.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain

8.5.3 Roche Holding AG: Financial Performance

8.5.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)

8.5.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)

8.5.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)

8.5.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)

8.5.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)

8.5.4 Roche Holding AG: Business Strategy

8.5.4.1 Product Level Strategy

8.5.5 SWOT Analysis of Roche Holding AG

Strengths

Weaknesses

Opportunities

Threats

8.5.6 Key Customers of Roche Holding AG

### **8.6 Merck & Co., Inc.**

8.6.1 Company Profile

- 8.6.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
- 8.6.3 Merck & Co., Inc.: Financial Performance
  - 8.6.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
  - 8.6.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
  - 8.6.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
  - 8.6.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
- 8.6.4 Merck & Co., Inc.: Business Strategy
  - 8.6.4.1 Product Level Strategy
- 8.6.5 SWOT Analysis of Merck & Co., Inc.

Strengths

Weaknesses

Opportunities

Threats

## **8.7 UCB S.A.**

- 8.7.1 Company Profile
- 8.7.2 UCB S.A. in Pharmaceutical Manufacturing Value Chain
- 8.7.3 UCB S.A. Financial Performance
  - 8.7.3.1 UCB S.A.: Overall Revenue FY 2013-FY 2019 (in USD billion)
  - 8.7.3.2 UCB S.A.: Geography-Wise Revenue FY 2018 (in USD billion)
  - 8.7.3.3 UCB S.A.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
- 8.7.4 UCB S.A.: Business Strategy
  - 8.7.4.1 Product Level Business Strategy
- 8.7.6 SWOT Analysis of UCB S.A.

Strengths

Weaknesses

Opportunities

Threats

## **8.8 AbbVie Inc.**

- 8.8.1 Company Profile
- 8.8.2 AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
- 8.8.3 AbbVie Inc.: Financial Performance
  - 8.8.3.1 AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
  - 8.8.3.2 AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
  - 8.8.3.3 AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
- 8.8.4 AbbVie Inc.: Business Strategy
  - 8.8.4.1 Product Level Strategy
- 8.8.5 SWOT Analysis of AbbVie Inc.

Strengths

Weaknesses

Opportunities

Threats

## **8.9 Eli Lilly and Company**

- 8.9.1 Company Profile
- 8.9.2 Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
- 8.9.3 Eli Lilly: Financial Performance
  - 8.9.3.1 Eli Lilly: Overall Revenue FY 2013-FY 2019 (in USD billion)
  - 8.9.3.2 Eli Lilly: Geography-Wise Revenue FY 2018 (in USD billion)
  - 8.9.3.3 Eli Lilly: Division-Wise Revenue FY 2018 (in USD billion)
  - 8.9.3.4 Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
  - 8.9.3.5 Eli Lilly: Therapy Area-Wise Revenue FY 2018 (in USD billion)
- 8.9.4 Eli Lilly: Business Strategy

- 8.9.4.1 Product Level Strategy
- 8.9.5 SWOT Analysis of Eli Lilly and Company
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats

## **8.10 Bristol-Myers Squibb Company**

- 8.10.1 Company Profile
- 8.10.2 Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
- 8.10.3 Bristol-Myers Squibb Company: Financial Performance
  - 8.10.3.1 Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019 (in USD billion)
  - 8.10.3.2 Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018 (in USD billion)
  - 8.10.3.3 Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
- 8.10.4 Bristol-Myers Squibb Company: Business Strategy
  - 8.10.4.1 Product Level Strategy
- 8.10.5 SWOT Analysis of Bristol-Myers Squibb Company
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats

## **9. Competitive Landscape in Global Antirheumatics Market**

- 9.1 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatics Revenue
- 9.2 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue
- 9.3 Competitive Landscape Among Top 10 Antirheumatics Companies by Global Pharmaceuticals Revenue
- 9.4 Competitive Landscape Among Top 10 Antirheumatics Companies by United States Revenue
- 9.5 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Development (R&D) Expenditure
- 9.6 Competitive Landscape Among Top 10 Antirheumatics Companies by Earning Per Share (EPS)
- 9.7 Competitive Landscape Among Top 10 Antirheumatics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
- 9.8 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue Forecast
- 9.9 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatic Product Revenues

## **10. Analysis of Global Antirheumatics Market**

- 10.1 Porter's Five Forces Analysis of Global Antirheumatics Market
- 10.2 SWOT Analysis of Global Antirheumatics Market
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats

## **11. Current and Future Trends in Global Antirheumatics Market**

- List of Exhibits
- Notes
- Company Information

## List of Exhibits

- Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
- Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
- Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
- Exhibit 2.4 Global Pharmaceuticals Industry Value Chain Analysis
- Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
- Exhibit 3.2 Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
- Exhibit 4.1 Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
- Exhibit 4.2 Forecast for Global Antirheumatics Pharmaceutical Market 2018-2023 (in USD billion)
- Exhibit 5.1 Growth Drivers and Inhibitors for Global Antirheumatics Pharmaceutical Market
- Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
- Exhibit 7.1 Key Information of EFPIA
- Exhibit 7.2 Contact details of EFPIA
- Exhibit 7.3 List of EFPIA Members
- Exhibit 7.4 Key Information of IFPMA
- Exhibit 7.5 Contact details of IFPMA
- Exhibit 7.6 List of IFPMA Members
- Exhibit 7.7 Key Information of PhRMA
- Exhibit 7.8 Contact details of PhRMA
- Exhibit 7.9 List of PhRMA Members
- Exhibit 7.10 Key information of ABPI
- Exhibit 7.11 Contact details of ABPI
- Exhibit 7.12 List of ABPI Members
- Exhibit 7.13 Key Information of JPMA
- Exhibit 7.13 Key Information of JPMA
- Exhibit 7.15 List of JPMA Members
- Exhibit 7.16 Key information of IDMA
- Exhibit 7.17 Contact details of IDMA
- Exhibit 8.1 Key Information of Pfizer Inc.
- Exhibit 8.2 Contact information of Pfizer Inc.
- Exhibit 8.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
- Exhibit 8.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
- Exhibit 8.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
- Exhibit 8.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
- Exhibit 8.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
- Exhibit 8.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)
- Exhibit 8.9 SWOT Analysis of Pfizer Inc.
- Exhibit 8.10 Key Information of Novartis AG
- Exhibit 8.11 Contact Information of Novartis AG
- Exhibit 8.12 Novartis AG in Pharmaceuticals Manufacturing Value Chain
- Exhibit 8.13 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
- Exhibit 8.14 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
- Exhibit 8.15 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
- Exhibit 8.16 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)
- Exhibit 8.17 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
- Exhibit 8.18 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
- Exhibit 8.19 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
- Exhibit 8.20 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
- Exhibit 8.21 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
- Exhibit 8.22 SWOT Analysis of Novartis AG



Exhibit 8.23 Key Information of Johnson & Johnson

Exhibit 8.24 Contact information of Johnson & Johnson

Exhibit 8.25 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain

Exhibit 8.26 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)

Exhibit 8.27 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)

Exhibit 8.28 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)

Exhibit 8.29 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)

Exhibit 8.30 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)

Exhibit 8.31 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)

Exhibit 8.32 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)

Exhibit 8.33 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)

Exhibit 8.34 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)

Exhibit 8.35 SWOT Analysis of Johnson & Johnson

Exhibit 8.36 Key information of Amgen Inc.

Exhibit 8.37 Contact details of Amgen Inc.

Exhibit 8.38 Amgen Inc. in Global Pharmaceuticals Manufacturing value chain

Exhibit 8.39 Revenue of Amgen Inc. FY 2013-FY 2019 (in USD billion)

Exhibit 8.40 Revenue Growth of Amgen Inc FY 2014-FY 2019 (in %)

Exhibit 8.41 Geography-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)

Exhibit 8.42 United States Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)

Exhibit 8.43 United States Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)

Exhibit 8.44 Rest of World Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)

Exhibit 8.45 Rest of World Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)

Exhibit 8.46 Division-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)

Exhibit 8.47 Pharmaceuticals Division Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)

Exhibit 8.48 Other Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)

Exhibit 8.49 Geography-Wise Pharmaceuticals Revenue of Amgen Inc in FY 2018 (in USD billion)

Exhibit 8.50 United States Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)

Exhibit 8.51 Rest of World Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)

Exhibit 8.52 Brand-Wise Pharmaceuticals Revenue of Amgen Inc FY 2018 (in USD billion)

Exhibit 8.53 SWOT Analysis of Amgen Inc.

Exhibit 8.54 Key Information of Roche Holding AG

Exhibit 8.56 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain

Exhibit 8.57 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)

Exhibit 8.58 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)

Exhibit 8.59 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)

Exhibit 8.60 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)

Exhibit 8.61 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)

Exhibit 8.62 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)

Exhibit 8.63 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)

Exhibit 8.64 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)

Exhibit 8.65 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)

Exhibit 8.66 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)

Exhibit 8.67 Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)

Exhibit 8.68 SWOT Analysis of Roche Holding AG

Exhibit 8.69 Roche Holding AG Pharmaceuticals Product Pipeline

Exhibit 8.70 Key Information of Merck & Co.

Exhibit 8.71 Contact Information of Merck & Co.

Exhibit 8.72 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain  
Exhibit 8.73 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)  
Exhibit 8.74 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)  
Exhibit 8.75 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)  
Exhibit 8.76 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)  
Exhibit 8.77 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)  
Exhibit 8.78 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)  
Exhibit 8.79 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)  
Exhibit 8.80 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)  
Exhibit 8.81 SWOT Analysis of Merck & Co., Inc.  
Exhibit 8.82 Key Information of UCB S.A.  
Exhibit 8.83 Contact information of UCB S.A.  
Exhibit 8.84 UCB S.A. in Pharmaceutical Manufacturing Value Chain  
Exhibit 8.85 Revenue of UCB S.A. FY 2013-FY 2019 (in USD billion)  
Exhibit 8.86 Revenue Growth of UCB S.A. FY 2014-FY 2019 (in %)  
Exhibit 8.87 Geography-Wise Revenue of UCB S.A. in FY 2018 (in USD billion)  
Exhibit 8.88 United States Revenue of UCB S.A. FY 2013-FY 2018 (in USD billion)  
Exhibit 8.89 United States Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)  
Exhibit 8.90 Europe Revenue of UCB S.A. FY 2013-FY 2018 (in USD billion)  
Exhibit 8.91 Europe Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)  
Exhibit 8.92 Rest of World Revenue of UCB S.A. FY 2014-FY 2018 (in USD billion)  
Exhibit 8.93 Rest of World Revenue Growth of UCB S.A. FY 2014-FY 2018 (in %)  
Exhibit 8.94 Therapy Area-Wise Revenue of UCB S.A. in FY 2018 (in USD billion)  
Exhibit 8.95 Therapy Area-Wise Revenue of UCB S.A. FY 2018 (in USD billion)  
Exhibit 8.96 UCB S.A. Product Pipeline  
Exhibit 8.97 SWOT Analysis of UCB S.A.  
Exhibit 8.98 Key information of AbbVie Inc.  
Exhibit 8.99 Contact Information of AbbVie. Inc.  
Exhibit 8.100 AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain  
Exhibit 8.101 Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)  
Exhibit 8.102 Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)  
Exhibit 8.103 Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)  
Exhibit 8.104 Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)  
Exhibit 8.105 Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)  
Exhibit 8.106 SWOT Analysis of AbbVie Inc.  
Exhibit 8.107 Key information of Eli Lilly  
Exhibit 8.108 Contact Information Eli Lilly  
Exhibit 8.109 Eli Lilly in Pharmaceuticals Manufacturing Value Chain  
Exhibit 8.110 Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion)  
Exhibit 8.111 Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)  
Exhibit 8.112 Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)  
Exhibit 8.113 United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)  
Exhibit 8.114 United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)  
Exhibit 8.115 Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)  
Exhibit 8.116 Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)  
Exhibit 8.117 Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)  
Exhibit 8.118 Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)  
Exhibit 8.119 Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)

Exhibit 8.120 Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)

Exhibit 8.121 United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)

Exhibit 8.122 Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)

Exhibit 8.123 Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)

Exhibit 8.124 Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)

Exhibit 8.125 Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)

Exhibit 8.126 Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)

Exhibit 8.127 SWOT Analysis of Eli Lilly and Company

Exhibit 8.128 Key Information of Bristol-Myers Squibb Company

Exhibit 8.129 Contact Information of Bristol-Myers Squibb Company

Exhibit 8.130 Bristol-Myers Squibb Company in Global Pharmaceuticals Manufacturing Value Chain

Exhibit 8.131 Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)

Exhibit 8.132 Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)

Exhibit 8.133 Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)

Exhibit 8.134 United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)

Exhibit 8.135 United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)

Exhibit 8.136 Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)

Exhibit 8.137 Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)

Exhibit 8.138 Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)

Exhibit 8.139 Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)

Exhibit 8.140 Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)

Exhibit 8.141 Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)

Exhibit 8.142 Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)

Exhibit 8.143 SWOT Analysis of Bristol-Myers Squibb Company

Exhibit 9.1 Competitive Landscape Among Top 10 Antirheumatics Companies by Antirheumatics Revenue for FY2018 (in USD billion)

Exhibit 9.2 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue for FY2018 (in USD billion)

Exhibit 9.3 Competitive Landscape Among Top 10 Antirheumatics Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)

Exhibit 9.4 Competitive Landscape Among Top 10 Antirheumatics Companies by United States Revenue for FY2018 (in USD billion)

Exhibit 9.5 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)

Exhibit 9.6 Competitive Landscape Among Top 10 Antirheumatics Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)

Exhibit 9.7 Competitive Landscape Among Top 10 Antirheumatics Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)

Exhibit 9.8 Competitive Landscape Among Top 10 Antirheumatics Companies by Overall Revenue Forecast for FY2019 (in USD billion)

Exhibit 9.9 Competitive Landscape Among Top 10 Antirheumatics Companies by Product-Wise Antirheumatics Revenue for FY2018 (in USD billion)

Exhibit 10.1 Porter's Five Forces Analysis for Global Antirheumatics Pharmaceutical Market

Exhibit 10.2 SWOT Analysis for Global Antirheumatics Pharmaceutical Market

1. **AbbVie Inc.**
2. **Amgen Inc.**
3. **Pfizer Inc.**
4. **Roche Holding AG**
5. **Novartis International AG**
6. **Johnson & Johnson**
7. **Bristol-Myers Squibb**
8. **Merck & Co., Inc.**
9. **UCB S.A.**
10. **Eli Lilly and Company**

### **Single User License (PDF)**

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

### **Site License (PDF)\***

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Enterprise license fee.

### **Enterprise License (PDF)\***

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

\*If Applicable.

## About Us



NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.

## Information

- [About Us](#)
- [Publications](#)
- [FAQs](#)
- [Privacy Policy](#)
- [Terms & Conditions](#)
- [Careers](#)
- [Press Releases](#)
- [Contact](#)

---

**Source URL:** <https://www.navadhi.com/publications/global-antirheumatics-pharmaceutical-market-forecast-2023>

### Links

[1] <https://www.navadhi.com/countries/global>